PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
ConditionProstate Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorAHS Cancer Control Alberta
About this trial
In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.
Eligibility criteria
Qualifiers
Participants capable of giving written informed consent.
Male.
Age ≥18 years.
ECOG ≤2.
Disqualifiers
Inability to complete the investigational imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.).
Any additional medical condition, serious inter-current illness or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study performance, interpretation, or compliance with radiation
Patients who have initiated therapy (ADT, systemic therapy, or radiation) for their prostate cancer prior to PSMA-PET imaging.
History of inflammatory bowel disease, anal stenosis, colorectal surgery, or repeated endoscopic examinations/interventions related to anorectal diseases.
Trial design
Treatments tested in this trial
- Prostate Only Radiation Therapy (PORT)
- Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
Treatment groups
250 Participants
are divided into 2 treatment groupsSponsors and collaborators
AHS Cancer Control Alberta
Lead sponsor
Cross Cancer Institute
Collaborator
Source ClinicalTrials.gov